Efficacy and Safety of Obinutuzumab in Adolescents with Active Lupus Nephritis: Primary Results from POSTERITY, a Phase II Global Trial (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #SA-OR073; Pres time: Oct 24, 2026; 04:30 PM - 04:42 PM; Location: Four Seasons Ballroom 2; P2, P3 | "Selected secondary endpoints included CRR at Week 24 and Week 52, CRR at Week 76 with successful prednisone taper (≤7.5 mg/day from Weeks 64–76), overall renal response at Week 76, and time to onset of CRR over 76 weeks. These results in a dedicated adolescent cohort with active class III or IV ± V LN support OBI as a potential targeted intervention in a population with limited treatment options."
Clinical • Late-breaking abstract • P2 data • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology
|
|
Marina Vivarelli1; Agustin Remesal12; Louise Oni13,14; Peiqing Yu15; Felix Erblang16; Olga Mitrofanova16; William Franklin Pendergraft17; Patricia B. Lehane18; Deborah Levy2,3; Gabriel Vega Cornejo4; Maria Teresa Terreri5; Aleksandra Zurowska6,7; Adolfina Elizabeth Zuta8; Joan Calzada-Hernández9; Julien Hogan10; Sandra Enciso-Peláez11
|